



## Xencor to Participate at Upcoming Investor Conferences

February 23, 2026

PASADENA, Calif.--(BUSINESS WIRE)--Feb. 23, 2026-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will participate at multiple upcoming investor conferences:

- TD Cowen 46th Annual Health Care Conference  
Date: Monday, March 2, 2026  
Presentation Time: 3:50 p.m. ET / 12:50 p.m. PT
- Leerink Partners 2026 Global Healthcare Conference  
Date: Tuesday, March 10, 2026  
Presentation Time: 10:00 a.m. ET / 7:00 a.m. PT
- Barclays 28th Annual Global Healthcare Conference  
Date: Wednesday, March 11, 2026  
Presentation Time: 11:30 a.m. ET / 8:30 a.m. PT

Live webcasts of the presentations will be available under "Events & Presentations" in the Investors section of the Company's website located at [www.xencor.com](http://www.xencor.com). Replays of the events will be available on the Xencor website for at least 30 days following the presentations.

### About Xencor

Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of patients with cancer and autoimmune diseases. More than 20 candidates engineered with Xencor's XmAb® technology are in clinical development, and multiple XmAb medicines are marketed by partners. Xencor's XmAb engineering technology enables small changes to a protein's structure that result in new mechanisms of therapeutic action. For more information, please visit [www.xencor.com](http://www.xencor.com).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20260223328030/en/): <https://www.businesswire.com/news/home/20260223328030/en/>

Charles Liles  
[cliles@xencor.com](mailto:cliles@xencor.com)  
(626) 737-8118

Source: Xencor, Inc.